2018 update of the EULAR recommendations for the management of Behçet's syndrome
Gülen Hatemi(Center for Rheumatology), Hasan Yazıcı(Istanbul University), Petros P. Sfikakis(National and Kapodistrian University of Athens), Pietro Leccese(Ospedale Madonna Delle Grazie), Francesco Scuderi, Aykut Ferhat Çelık(Istanbul University-Cerrahpaşa), Yeşim Özgüler(Istanbul University), Robin Christensen(University of Copenhagen), Carlo Salvarani(Sorbonne Université), Sebahattin Yurdakul(Istanbul University), Alfred Mahr(Kantonsspital St. Gallen), Ina Kötter(Eppendorf (Germany)), Ignazio Olivieri(Ospedale Madonna Delle Grazie), Aksel Sıva(Koç University), Julien Gaudric(Sorbonne Université), Miles Stanford(Imperial College Healthcare NHS Trust), Dongsik Bang(Catholic Kwandong University International St. Mary's Hospital), Robert J. Moots(Edge Hill University), David Saadoun(Sorbonne Université), Bahram Bodaghi(Sorbonne Université), Richard West(Intensive Care Society), Jutta Richter, İlknur Tuğal-Tutkun(Azienda Ospedaliera Universitaria Pisana), Farida Fortune(Queen Mary University of London), Ahmet Gül(Istanbul University)
Cited by 771
Related Papers
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
|The Lancet|2007|1.1k
GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomes
|Journal of Clinical Epidemiology|2012|761
The Long-Term Mortality and Morbidity of Behçet Syndrome
|Medicine|2003|757
EULAR recommendations for the management of Behçet disease
|Annals of the Rheumatic Diseases|2008|721